Repurposing Drugs to Treat COVID-19

“Many re-purposed drugs have failed in clinical trials for COVID-19,” said Associate Professor James Hudson, head of the Cardiac Bioengineering Research Group at QIMR Berghofer. “We sought a different approach to firstly understand mechanistically how COVID-19 could be driving cardiac dysfunction seen in many patients. After detailed studies we identified bromodomain-containing protein 4 as a key mediator of dysfunction and BET inhibitors were very effective at blocking this response. In the pursuit to translate these findings to the clinic, we formed a very exciting collaboration with Resverlogix to test apabetalone, which we also found was very effective in our models. It was a pleasure to work with Resverlogix and truly share information both ways, and contribute data for the basis of their clinical trials.”

WHAT HAPPENS NOW?  Sitting on Gold Mine, will it ever shine?

Are we looking for another test, still waiting for the finish line.  RVX has more potential, still patient, but like some here, wondering if we will ever see the day.  The BOD needs to represent stockholders better.